AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 141 min read$LGND

Haas Jason sold $2.1M of LGND

Haas Jason sold 7,138 shares of LIGAND PHARMACEUTICALS INC (LGND) at $292.81 ($2.09M total) on 2026-08-12.

Original reporting
SEC EDGAR · Haas Jason
Published Aug 14, 2026, 9:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 11:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$LGND
Neutral
medium confidence
Mentioned
$LGND
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LGNDNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but this filing alone does not change Ligand’s fundamentals or near-term expectations.

02

Market read

A director open-market sale of about $2.09M is disclosed, which can slightly pressure sentiment but lacks fundamental catalysts.

03

What to watch

No 10b5-1 plan is cited, but the filing does not disclose intent, diversification needs, or whether other insiders are selling/buying concurrently.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-14, transaction dated 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for Ligand Pharmaceuticals, reported via SEC EDGAR.

Company-level read

Ticker impact

$LGNDNeutralMedium confidence
Context

SEC Form 4 shows director Jason Haas sold 7,138 shares of Ligand Pharmaceuticals at $292.8078 on 2026-08-12.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The transaction is a director sale with no 10b5-1 plan stated and no accompanying company news, so it is typically viewed as low-signal unless part of a broader pattern.

Market effects

Sector

Minimal; this is company-specific insider activity with no disclosed sector-wide regulatory or clinical development.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be routine liquidity or tax-related, especially without any stated link to company performance.

Key entities

  • issuer
    LGND

    Ligand Pharmaceuticals Inc., the company whose director insider sale is disclosed.

  • insider
    Haas Jason

    Director of Ligand Pharmaceuticals who sold shares in an open-market transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LGND insider trading history →

Related articles

AUG 13
$LGNDHighAI 9/10

Ligand (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 34%, driven by $48.0M royalty revenue (+32%). Adjusted diluted EPS was $2.37 (+48%). 2026 guidance raised to adjusted EPS $9.00-$9.50 and revenue $270M-$310M. Cash and short-term investments were $1.36B after a $700M convertible note. The XOMA Royalty acquisition added 120 assets.

fool.com6 min
AUG 8
$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

yahoo.com7 min
AUG 6
$LGNDMed

LIGAND PHARMACEUTICALS INC (LGND): Results of Operations and Financial Condition

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease_ex991.htm EX-99.1 Document Ligand Reports Second Quarter 2026 Financial Results Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Confer

SEC EDGAR 8-K6 min
JUL 14
$LGNDMedAI 9/10

XOMA Royalty Announces Closing of Its Acquisition by Ligand

XOMA Royalty said Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty. Under the April 27 deal, XOMA shareholders received $39.00 cash per share and one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation. XOMA shares no longer trade on Nasdaq.

manilatimes.net2 min
JUL 14
$LGNDMedAI 9/10

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty for $39.00 per share in cash, totaling about $739 million equity value, plus one CVR per share tied to 75% of net litigation proceeds. The deal adds seven commercial products and 100+ development assets, expanding its portfolio to 200+ royalties. Expected EPS accretion: +$0.50 (2026) and +$1.50 (2027).

manilatimes.net3 min
JUL 14
$LGNDMed

LIGAND PHARMACEUTICALS INC (LGND): Completion of Acquisition or Disposition of Assets

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K LIGAND PHARMACEUTICALS INC false 0000886163 0000886163 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest

SEC EDGAR 8-K4 min